Standout Papers

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gas... 2023 2026 2024283
  1. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
    Kohei Shitara, Florian Lordick et al. The Lancet

Immediate Impact

56 standout
Sub-graph 1 of 22

Citing Papers

Pancreatic cancer
2025 Standout
Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection
2025 Standout
2 intermediate papers

Works of Mok Oh being referenced

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis
2019

Author Peers

Author Last Decade Papers Cites
Mok Oh 236 254 124 24 545
Zizhen Zhang 182 193 100 35 582
Andriy Rusyn 277 202 102 16 463
Sang Ho Kim 229 104 101 32 649
Yusuke Okuda 178 84 117 32 514
William H. Falor 104 112 320 34 579
Xianbao Zhan 402 157 147 25 644
Saori Mishima 448 336 133 36 647
Keren Jia 280 174 78 19 472
Abderrahman Ouban 139 97 77 33 535
S-E. Al-Batran 213 288 173 21 464

All Works

Loading papers...

Rankless by CCL
2026